Medindia
Medindia LOGIN REGISTER
Advertisement

Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)

Saturday, April 19, 2008 General News
Advertisement
DETROIT, April 18 Caraco PharmaceuticalLaboratories, Ltd. (Amex: CPD) has confirmed that the United States DistrictCourt of New Jersey has granted Caraco's motion for summary judgment that theclaims of U.S. Patent No. 39,221 that Ortho-McNeil Pharmaceutical, Inc.asserted against Caraco are invalid. Caraco's Tramadol with Acetaminophenproduct is a generic version of Ortho-McNeil's Ultracet(R). The Companycommenced shipment of Tramadol with Acetaminophen following the FDA's approvalto manufacture, market and distribute the generic product on December 19,2005, and it has remained on the market since that time.
Advertisement

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets and distributes generic and private-labelpharmaceuticals to the nation's largest wholesalers, distributors, drugstorechains and managed care providers.
Advertisement

Safe Harbor: This news release contains forward-looking statements madepursuant to the safe-harbor provisions of the Private Securities LitigationReform Act of 1995. Such statements are based on management's currentexpectations and are subject to risks and uncertainties that could causeactual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in theCorporation's filings with the Securities and Exchange Commission and include,but are not limited to: information of a preliminary nature that may besubject to adjustment, potentially not obtaining or delay in obtaining FDAapproval for new products, governmental restrictions on the sale of certainproducts, development by competitors of new or superior products or cheaperproducts or new technology for the production of products, the entry into themarket of new competitors, market and customer acceptance and demand for newpharmaceutical products, availability of raw materials, timing and success ofproduct development and launches, dependence on few products generatingmajority of sales, product liability claims for which the Company may beinadequately insured, and other risks identified in this report and from timeto time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. Wedisclaim, however, any intent or obligation to update our forward-lookingstatements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close